Key Insights

Highlights

Success Rate

96% trial completion (above average)

Published Results

43 trials with published results (12%)

Research Maturity

216 completed trials (58% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

2.7%

10 terminated out of 372 trials

Success Rate

95.6%

+9.1% vs benchmark

Late-Stage Pipeline

20%

74 trials in Phase 3/4

Results Transparency

20%

43 of 216 completed with results

Key Signals

43 with results96% success

Data Visualizations

Phase Distribution

298Total
Not Applicable (153)
Early P 1 (2)
P 1 (37)
P 2 (32)
P 3 (31)
P 4 (43)

Trial Status

Completed216
Unknown63
Recruiting43
Active Not Recruiting18
Terminated10
Withdrawn9

Trial Success Rate

95.6%

Benchmark: 86.5%

Based on 216 completed trials

Clinical Trials (372)

Showing 20 of 20 trials
NCT07644910Not ApplicableNot Yet Recruiting

Nudging Preventive Screening Via Message Framing and Bundling

NCT07634510Phase 1Not Yet RecruitingPrimary

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MWX205

NCT07614659Not ApplicableRecruiting

Uppsala Self-Screening of Cardiovascular Health (U-SCREEN)

NCT07491172Phase 1Recruiting

A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias

NCT06183307Not ApplicableRecruiting

Effects of Nattokinase on Inflammation and Cardiovascular Risk Markers in Patients With Dyslipidemia

NCT05413135Phase 2CompletedPrimary

Study of ARO-APOC3 in Adults With Dyslipidemia

NCT06697977Not ApplicableCompleted

Effects of Phytosterol Supplementation on Liver Function and Inflammatory Status in Patients With Nonalcoholic Fatty Liver Disease

NCT05365438Phase 4RecruitingPrimary

Atmeg (Atorvastatin and Omega-3 Combination) and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia

NCT03794531Recruiting

Psychosocial, Environmental, and Chronic Disease Trends in Puerto Rico

NCT06657456Not ApplicableCompleted

Impact of Phytosterol-Rich Extract on Lipid Profile

NCT05949879Not ApplicableCompletedPrimary

Dose Response Effects of Pecan Consumption

NCT05686954Not ApplicableCompletedPrimary

Cottonseed Oil Dose Response

NCT05881447Recruiting

Prevalence, Incidence and Risk Signature of Chronic Kidney Disease in Sub-Saharan Africa

NCT07551505Phase 1Not Yet RecruitingPrimary

Safety, PK, and PD of BSA204 in Chinese Adults With Borderline Elevated Lipoprotein(a)

NCT03903029CompletedPrimary

Efficacy of Low-dose (10 mg) Rosuvastatin in Korean 4 Statin Benefit Groups Per 2013 ACC/AHA Guideline

NCT07551960Not ApplicableEnrolling By Invitation

Pilot Validation of the STELA Preventive Medicine Platform to Reduce Modifiable Health Risk Factors in Adults (CPM-STELA)

NCT03860220Phase 4Completed

The Efficacy and Safety of Triple Therapy of Telmisartan/Amlodipine/Rosuvastatin

NCT07543718Not ApplicableRecruitingPrimary

Group Medical Visits for Patients With Dyslipidemia

NCT05622929Not ApplicableCompleted

Cluster Randomized Trial of a Digital Quality Improvement Intervention on LDLCholesterol Control

NCT04634591Recruiting

The Bialystok Bariatric Surgery Study

Scroll to load more

Research Network

Activity Timeline